Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009)

Diagnostic Microbiology and Infectious Disease

Volumn 72, Issue 1, 2012, Pages 113-117

  Mendes, Rodrigo E ^a   Sader, Helio S ^a   Farrell, David J ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gram positive; Lipoglycopeptide; Staphylococcus aureus; Telavancin; USA

Indexed keywords

AMPICILLIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; TEICOPLANIN; TELAVANCIN; TETRACYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS CONSTELLATUS; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS EQUI; STREPTOCOCCUS GORDONII; STREPTOCOCCUS GROUP A; STREPTOCOCCUS GROUP C; STREPTOCOCCUS GROUP F; STREPTOCOCCUS GROUP G; STREPTOCOCCUS INTERMEDIUS; STREPTOCOCCUS MILLERI; STREPTOCOCCUS MITIS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS ORALIS; STREPTOCOCCUS PARASANGUINIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS SANGUINIS; STREPTOCOCCUS THERMOPHILUS; STREPTOCOCCUS UBERIS; STREPTOCOCCUS VESTIBULARIS; UNITED STATES;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DAPTOMYCIN; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; UNITED STATES; VIRGINIAMYCIN;

EID: 83055176336     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.09.023     Document Type: Article

References (18)

1. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard 2009, CLSI, M07-A8 Wayne, PA. 8th ed.
2. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: 21st Informational supplement 2011, CLSI, M100-S21 Wayne, PA.
3. Crandon J.L., Kuti J.L., Nicolau D.P. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob. Agents Chemother. 2010, 54:5115-5119.
4. Draghi D.C., Benton B.M., Krause K.M., Thornsberry C., Pillar C., Sahm D.F. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob. Agents Chemother. 2008, 52:2383-2388.
5. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, March 2011 Available at, Accessed March 18, 2011. http://www.eucast.org/clinical_breakpoints/.
6. Farrell D.J., Krause K.M., Benton B.M. In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci. Diagn. Microbiol. Infect. Dis. 2011, 69:275-279.
7. Hegde S.S., Skinner R., Lewis S.R., Krause K.M., Blais J., Benton B.M. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylcoccus aureus (hVISA) in vitro and an in vivo mouse model of bacteraemia. J. Antimicrob. Chemother. 2010, 65:725-728.
8. Higgins D.L., Chang R., Debabov D.V., Leung J., Wu T., Krause K.M., Sandvik E., Hubbard J.M., Kaniga K., Schmidt D.E., Gao Q., Cass R.T., Karr D.E., Benton B.M., Humphrey P.P. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2005, 49:1127-1134.
9. Krause K.M., Renelli M., Difuntorum S., Wu T.X., Debabov D.V., Benton B.M. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob. Agents Chemother. 2008, 52:2647-2652.
10. Leonard S.N., Szeto Y.G., Zolotarev M., Grigoryan I.V. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int. J. Antimicrob. Agents 2011, 37:558-561.
11. Leonard S.N., Vidaillac C., Rybak M.J. Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 2009, 53:2928-2933.
12. Lin G., Pankuch G.A., Ednie L.M., Appelbaum P.C. Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay. Antimicrob. Agents Chemother. 2010, 54:2201-2205.
13. Lunde C.S., Hartouni S.R., Janc J.W., Mammen M., Humphrey P.P., Benton B.M. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob. Agents. Chemother:. Antimicrob. Agents Chemother. 2009, 53:3375-3383.
14. Putnam S.D., Sader H.S., Moet G.J., Mendes R.E., Jones R.N. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagn. Microbiol. Infect. Dis. 2010, 67:359-368.
15. Reyes N., Skinner R., Benton B.M., Krause K.M., Shelton J., Obedencio G.P., Hegde S.S. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 2006, 58:462-465.
16. Rubinstein E., Lalani T., Corey G.R., Kanafani Z.A., Nannini E.C., Rocha M.G., Rahav G., Niederman M.S., Kollef M.H., Shorr A.F., Lee P.C., Lentnek A.L., Luna C.M., Fagon J.Y., Torres A., Kitt M.M., Genter F.C., Barriere S.L., Friedland H.D., Stryjewski M.E. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin. Infect. Dis. 2011, 52:31-40.
17. Stryjewski M.E., Graham D.R., Wilson S.E., O'Riordan W., Young D., Lentnek A., Ross D.P., Fowler V.G., Hopkins A., Friedland H.D., Barriere S.L., Kitt M.M., Corey G.R. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin. Infect. Dis. 2008, 46:1683-1693.
18. VIBATIV Package insert 2009, Theravance, Inc., South San Francisco, CA, Available at. http://www.theravance.com/index.php.